CD22 and acute lymphoblastic leukemia: CRISPR/Cas9 disrupted the TRAC region and CD52 gene-edited dual CD19/CD22 CAR-T cells also showed antitumor efficacy in patients with R/R B-ALL; and no CRISPR gene-editing-associated genotoxicity, immunogenicity, or GvHD was observed in this study [34].